Simcere Pharmaceutical Group (STU:S2P) Tariff Resilience Score: 0/10 (As of Jul. 25, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:S2P Simcere Pharmaceutical Group Ltd STU:S2P
94 GF Score
Price €1.38
GF Value €1.16
View Full Analysis

What is Simcere Pharmaceutical Group Tariff Resilience Score?

Simcere Pharmaceutical Group has the Tariff Resilience Score of 0, which implies that the company might have .

Simcere Pharmaceutical Group has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Simcere Pharmaceutical Group might have .

Simcere Pharmaceutical Group  (STU:S2P) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Simcere Pharmaceutical Group Tariff Resilience Score Related Terms

STU:S2P
94GF Score
Simcere Pharmaceutical Group Ltd STU:S2P
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Simcere Pharmaceutical Group (STU:S2P) Overvalued in 2026?

Based on GuruFocus' analysis, Simcere Pharmaceutical Group stock appears to be overvalued. The current stock price of €1.38 is trading 19% above its estimated GF Value™ of €1.16.

Key valuation signals for STU:S2P:

  • Tariff Resilience Score: 0
  • GF Value™: €1.16 vs. price of €1.38 (19% above fair value)
  • GF Score™: 94/100

No single metric tells the full story. See the STU:S2P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Simcere Pharmaceutical Group Business Description

Other Exchanges 02096:Hong Kong
Address No. 699-18, Xuanwu Road, Xuanwu District, Jiangsu Province, Nanjing, CHN, 210042
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. The company has a diversified product portfolio focused on therapeutic areas, including, neuroscience, anti-oncology, autoimmune, and antiinfection. The company's products include Endostar, Enweida, Enzeshu, Iremod, Quviviq, Cosela, Sanbexin and Others.
94GF Score

Get the complete analysis for STU:S2P

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.38
Price
€1.16
GF Value